X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2880) 2880
Book Review (817) 817
Publication (269) 269
Book Chapter (15) 15
Conference Proceeding (10) 10
Magazine Article (4) 4
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2307) 2307
cetuximab (2258) 2258
humans (2205) 2205
oncology (1885) 1885
colorectal cancer (1403) 1403
chemotherapy (1221) 1221
colorectal neoplasms - drug therapy (1191) 1191
female (1071) 1071
male (1048) 1048
cancer (996) 996
middle aged (946) 946
aged (900) 900
colorectal neoplasms - pathology (866) 866
1st-line treatment (777) 777
antineoplastic combined chemotherapy protocols - therapeutic use (755) 755
bevacizumab (702) 702
metastasis (698) 698
adult (693) 693
colorectal neoplasms - genetics (677) 677
antineoplastic agents - therapeutic use (663) 663
antibodies, monoclonal, humanized (657) 657
mutation (632) 632
growth-factor receptor (610) 610
antibodies, monoclonal - therapeutic use (605) 605
care and treatment (592) 592
fluorouracil (590) 590
panitumumab (588) 588
oxaliplatin (587) 587
treatment outcome (579) 579
receptor, epidermal growth factor - antagonists & inhibitors (518) 518
irinotecan (499) 499
cetuximab plus irinotecan (493) 493
leucovorin (471) 471
metastatic colorectal-cancer (460) 460
kras (457) 457
camptothecin - analogs & derivatives (451) 451
neoplasm metastasis (446) 446
aged, 80 and over (422) 422
research (422) 422
ras proteins - genetics (415) 415
antibodies, monoclonal - administration & dosage (407) 407
disease-free survival (405) 405
egfr (393) 393
prognosis (384) 384
epidermal growth factor (381) 381
proto-oncogene proteins p21 (380) 380
tumors (376) 376
therapy (373) 373
drug therapy (368) 368
proto-oncogene proteins - genetics (368) 368
survival (360) 360
medicine & public health (358) 358
monoclonal antibodies (358) 358
phase-iii trial (354) 354
camptothecin - administration & dosage (335) 335
plus irinotecan (330) 330
analysis (328) 328
digestive system diseases (314) 314
pharmacology & pharmacy (307) 307
health aspects (306) 306
colorectal neoplasms - mortality (303) 303
fluorouracil - administration & dosage (294) 294
hematology, oncology and palliative medicine (290) 290
genetic aspects (287) 287
cancer therapies (281) 281
neoplasms (277) 277
antineoplastic agents (276) 276
trial (276) 276
metastatic colorectal cancer (268) 268
open-label (266) 266
antibodies, monoclonal - adverse effects (264) 264
receptor, epidermal growth factor - metabolism (264) 264
antimitotic agents (261) 261
antineoplastic combined chemotherapy protocols - adverse effects (261) 261
animals (256) 256
cell lung-cancer (249) 249
expression (249) 249
patients (245) 245
retrospective studies (245) 245
organoplatinum compounds - administration & dosage (242) 242
liver neoplasms - secondary (233) 233
clinical trials (230) 230
phase-ii trial (223) 223
antineoplastic agents - adverse effects (221) 221
surgery (221) 221
cancer research (219) 219
antineoplastic combined chemotherapy protocols - administration & dosage (218) 218
proto-oncogene proteins b-raf - genetics (215) 215
combination (211) 211
colorectal carcinoma (207) 207
braf (206) 206
metastases (203) 203
colon-cancer (198) 198
antineoplastic agents - pharmacology (194) 194
epidermal growth factor receptor (193) 193
neoplasm staging (192) 192
capecitabine (191) 191
survival rate (190) 190
colorectal neoplasms - metabolism (189) 189
cancer patients (186) 186
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2814) 2814
French (30) 30
German (22) 22
Japanese (15) 15
Spanish (4) 4
Chinese (3) 3
Korean (2) 2
Italian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4697 - 4705
Purpose Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved... 
KRAS MUTATIONS | MCRC | ONCOLOGY | STATISTICS | CETUXIMAB PLUS IRINOTECAN | CHEMOTHERAPY CT | OPEN-LABEL | COMBINATION | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Colorectal Neoplasms - mortality | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 2014, Volume 20, Issue 4, pp. 430 - 435
Journal Article
BMC Cancer, ISSN 1471-2407, 08/2009, Volume 9, Issue 1, pp. 303 - 303
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2009, Volume 9, Issue 1, pp. 112 - 112
Background: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with... 
LIVER METASTASES | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | PLUS IRINOTECAN | ONCOLOGY | KRAS STATUS | OXALIPLATIN | II TRIAL | FLUOROURACIL | CHEMOTHERAPY | CLINICAL-RELEVANCE | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Exanthema - chemically induced | Colorectal Neoplasms - drug therapy | Leukopenia - chemically induced | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Drug Administration Schedule | Treatment Outcome | Disease Progression | Vomiting - chemically induced | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Colorectal Neoplasms - pathology | Antimitotic agents | Patient outcomes | Colorectal cancer | Development and progression | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Health aspects | Index Medicus
Journal Article
Journal Article
Cancer Discovery, ISSN 2159-8274, 11/2011, Volume 1, Issue 6, pp. 508 - 523
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 601 - 611
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1755 - 1762
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2016, Volume 78, Issue 3, pp. 585 - 593
Journal Article
Journal Article